988-3 Is there a Circadian Variation in Anticoagulation Response to Hirudin Following Acute Myocardial Infarction?  by Henry, Timothy D. et al.
310A ABSTRACfS lACC February 1995
Group 1/Group IGroup IIGroup I
The beneficial effect of aspirin (ASA) in unstable angina is well established,
yet data on effect of ASA during the hyperacute phase of myocardial infarc-
tion (AMI) is limited. We evaluated the effect of early chewed ASA adminis-
tration on reperfusion rate and hospital outcome in 90 consecutive AMI pa-
tients treated at home or in the Emergency Room. All patients had ischemic
chest pain of :0:30 minutes, associated with :0:2 mm STt. Early reperfusion
within 30 minutes occurred in 42 patients (46.7%); only 3 patients needed
thrombolysis. In 27 controls reperfusion occurred in 7 patients (25.9%); p
= 0.05. No difference in hospital outcome was observed between patients
with ASA-induced reperfusion and patients treated by thrombolytics.
Conclusion: 1) Chewed ASA taken early in the hyperacute phase of AMI
induced sustained reperfusion in a significant number of patients (46.7%);
2) The above results call for on-scene early administration of chewed ASA in
all suspected AMI patients.
Pawel Buszman, Mariusz GasiDr, Andrzej Wnek, Zbigniew Kalarus,
Stanislaw Pasyk. Silesian Center of Cardiology, Zabrze, Poland
The aim of this study was to assess the influence of pre-hospital treatment
with intravenDus heparin on the early patency rate olthe infarct related artery
in acute myocardial infarction. The inclusion criteria were: beginning of chest
pain in the 6 hDurs preceding admission, ST segment elevation :0: 1 mm in at
least two leads of the standard ECG and no contraindications to antithrom-
botic treatment. One hundred and twenty four patients with these criteria
were divided into 2 groups. Forty five patients (group I) were treated with
5,000 units of heparin Lv. befDre admission tD hospital. Seventy nine patients
(group II) did not receive heparin before hospitalisation. All patients in both
groups were put on Aspirin 150 mg p.o., nitro-glycerine and analgesics be-
fore admission. The mean period from the beginning of the chest pain was
2.7 ± 1.5 hour in group I and 2.8 ± 1.4 hour in group II (p = NS). Both groups
did not differ in relation to age, sex, risk factors and previous incidence of
myocardial infarction. In the emergency room all patients were put on hep-
arin and nitro-glycerine infusions Lv. and were transferred immediately to the
catheterisation laboratory for cDronary angiography. The flow through the in-
farct related artery was assessed according to the TIM I classification. Patent
infarct related arteries (i.e. TIMI flow grade I, 2 or 3) were observed in 19 pa-
tients (42.2%) in group I and in 18 (22.8%) in group II (p = 0.038). Successful
reperfusion (defined as TIMI grade 2 Dr 3) was present in 11 patients (24.4%)
in group I and in 7 (8.8%) in group II (p = 0.035).
.TIMI2,3 CTIMIO,1I
This pilot study suggests that pre-hospital treatment with intravenous hep-
arin can significantly improve flow in infarct related arteries. A prospective
randomised study is needed to confirm these results.
Aspirin-induced Reperfusion in Acute Myocardial
Infarction
Arieh Freifeld, Babeth Rabinowitz, Elieser Kaplinsky, Michal Benderly,
Michael ScheinDwitz, Oren Agranat, Dov Freimark, Hanoch Hod. Heart Institute,
Sheba Medical Center, Tel-Hashomer, Israel
Influence of Pre-Hospital Heparinisation on Early
Patency Rate of Infarct Related Artery in Acute
Myocardial Infarction
We have previously shown that regional myocardial ischemia foliDwed by
reperfusion (rep) significantly enhances cardiac release of the potent vaso-
constrictor endothelin (ET). We now examine the association of ET produc-
tion and myocardial blood flow IMBF) in rabbits (n = 14) undergoing 30 min
Df circumflex occlusion and 3 hrs of rep. MBF was measured with radioac-
tive microspheres at baseline, 15 min into occlusion, 1 min, 1 and 3 hrs into
rep. Utilizing molecular biology techniques, ET1 mRNA was measured at 3
hrs and found to be elevated in the central ischemic zone (CIZ) compared to
the non ischemic zone INIZ). In a second study we investigated the effects
of exogenous ETl and PD145065 (an ETA/B receptor antagonist) on infarct
size of rabbits undergoing 30 min of circumflex occlusion and 48 hrs of rep.
Endothelin ETA/B Receptor Antagonist Reduces
Infarct Size: A Novel Therapy for Acute Myocardial
Infarction
JDaD V. VltDla, JDhn HDlsinger, Menryn B. FDrman, Edwin K. JacksDn,
Masatoshi Kawana, ThDmas QuertermDus, John J. Murray. Vanderbilt University,
Nashville, TN; University of Pittsburgh, Pittsburgh, PA
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Dose 00: 00-06: 00 06:00-12:00 12:00-18:00 18:00-24:00
0.05 63± -14 (64) 67 ± -18 (69) 62 ± -16 (69) 66±-16 (58)
0.10 81 ± -21 (60) 75 ± -21 (70) 74 ± -19 (59) 72 ± -21 (71)
0.20 83 ± -12 (16) 94 ± -23 (4) 79 ± -16 (18) 73 ± 12 (4)
Total 73 ± -19 (140) 72 ± -21 (143) 69±-19(146) 69 ± -19 (133)
There were no significant differences in aPTT results within dosing groups
or the total patient population for the designated time periods. Conclusion:
Unlike heparin, there does not appear to be a circadian variation in anticoag-
ulant response to hirudin in patients with acute myocardial infarction. This
may contribute to the improved stability in aPTIs observed with hirudin and
has potential clinical importance for both bleeding and thrombotic events.
Is there a Circadian Variation in Anticoagulation
Response to Hirudin Following Acute Myocardial
Infarction?
IX, and XI, by suppressing thrombin generation, may be an important goal
for future management of acute coronary syndromes.
6 hr aPTT (sees)
Timothy D. Henry, Richard C. Becker, Christopher P. Cannon, Carolyn H. McCabe,
Joseph Loscalzo, TIMI5 Investigators. Hennepin County Medical Center,
Minneapolis, MN
There is a well-described circadian variation in the occurrence of acute
thrombotic coronary syndromes. Likewise, a circadian variation in anticoag-
ulant response to heparin has been reported with a peak effect between
00:00 and 04:00 and a nadir 08:00 to 12:00 hours. This contributes to vari-
ability in aPTI's and may be clinically important. predisposing to increased
thrombotic events in the morning and bleeding events at night. The reason
for this variation is unclear. TIMI-5 was a pilot trial of hirudin, a specific di-
rect thrombin inhibitor, with t-PA and aspirin in acute myocardial infarction.
To determine if a circadian variation in anticoagulant response to hirudin is
present, we examined aPTI results obtained using Ciba-Corning 512 monitor
every 12 hours during the 5-day constant infusion in 87 patients at 3 different
fixed infusion rates (0.05, 0.10,0.20 mg/kg/hr). Data for aPTIs drawn during
4 time periods are expressed in seconds: mean ± SD (# of aPTIs).
Hemorrhagic Stroke Associated with High aPTTs
Following Thrombolytic Therapy and Heparin or
Hirudin
Cristopher Granger, Frans Van de Wert, Mark Horrigan, Robert Califf,
Lynn WDodlief, Eric TDPDI, GUSTO Iia Investigators. Duke University Med":al Center,
Durham, NC
In GUSTO Ila, 2564 patients with acute coronary syndrome with ST devia-
tiDn and symptoms within 12 hours were randomized to hirudin (0.6 mg/kg
bolus, 0.6 mglkg/hr infusiDn with out adjustment) or IV heparin (5,000 U bo-
lus, 1100 to 1300 U/hr adjusted tD a target aPTF of 60-90 seconds) for 3-5
days. The 26 patients who suffered hemorrhagic stroke, as expected from
previous studies examining risk factors, were older (median age 71 vs 65).
had higher initial systolic blood pressure (142 vs 134 mmHg) and were more
commonly female (42 vs 31 %). Unexpectedly, hemorrhagic stroke patients
weighed more (82 vs 77 kg), which may have reflected weight-adjusted dos-
ing and consequent administration of more anticoagulant. Of the 26 patients,
23 were treated with thrombolytic therapy. In spite of concern over renal
dysfunction contributing to increased risk, the baseline and 48 hour creati-
nine was similar among hirudin treated patients with (1.2,1.21 and without
(1.1,1.1) hemorrhagic stroke. APTT was a predictor of hemorrhagic stroke,
particularly in the hirudin assigned group:
Multivariable analysis will help to determine the relative importance of risk
factors in GUSTO lIa for hemorrhagic stroke, and whether the elevated aPTTs
appear to fully explain the increased risk. These data illustrate the narroW
therapeutic window for antithrombin therapy in conjuction with thromboly-
sis.
